Form 4: Cumberland Pharmaceuticals Executive Reports Stock Transactions

Chris T. Bitterman, Vice President of Sales & Marketing at Cumberland Pharmaceuticals, reports the acquisition and disposal of company stock to cover tax obligations and the acquisition of options.

Summary

• Chris T. Bitterman, Vice President of Sales & Marketing at Cumberland Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 23, 2024, 593 shares of common stock were disposed of at a price of $1.81 to cover tax withholding obligations.
• Following this transaction, Bitterman directly owns 4,683 shares of common stock.
• On March 25, 2024, Bitterman acquired options to buy 2,750 shares of common stock at an exercise price of $1.71, exercisable from March 25, 2028, and expiring on March 25, 2034.
• Following this transaction, Bitterman directly owns 13,250 options.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they primarily relate to executive compensation and tax obligations.
• Shareholders may be interested in the filing as it provides insight into executive stock ownership.

Key Dates